SummaryThis is a non-randomised, open-label study investigating the effects of different regimens of chemotherapy in people with newly diagnosed stage II-IV diffuse anaplastic Wilm's tumours (DAWT) or relapsed favourable histology Wilm's Tumours (FHWT). Participants will DAWT and standard-risk relapsed FHWT will receive the UH-3 chemotherapy regimen, which includes vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan. Participants with high- and very-high risk FHWT will receive the ICE/Cyclo/Tropo chemotherapy regimen, which includes ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan. All treatments will be administered intravenously (via IV).
This trial is treating patients with Wilm's tumour.
Use the hyperlinks, where available to access additional clinical trial information.
National Cancer Institute (NCI), Children's Oncology Group
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)